{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:16:04Z","timestamp":1773537364558,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K11428"],"award-info":[{"award-number":["17K11428"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["H29-Nanchi-Ippan-050"],"award-info":[{"award-number":["H29-Nanchi-Ippan-050"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["H29-Nanchi-Ippan-050"],"award-info":[{"award-number":["H29-Nanchi-Ippan-050"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10384-021-00872-2","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T11:26:01Z","timestamp":1632914761000},"page":"843-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Beh\u00e7et\u2019s disease in long-term remission"],"prefix":"10.1007","volume":"65","author":[{"given":"Yasutsugu","family":"Ida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Hasumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"872_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD). The international criteria for Behcet\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"872_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Behcet\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"872_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB. Uveitis in Behcet\u2019s disease. Int Rev Immunol. 1997;14:67\u201379.","journal-title":"Int Rev Immunol"},{"key":"872_CR4","first-page":"225","volume":"77","author":"S Mishima","year":"1979","unstructured":"Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet\u2019s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225\u201379.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"872_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005;50:297\u2013350.","journal-title":"Surv Ophthalmol"},{"key":"872_CR6","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318.","journal-title":"Ann Rheum Dis"},{"key":"872_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1517\/14656566.3.7.845","volume":"3","author":"V Saravanan","year":"2002","unstructured":"Saravanan V, Hamilton J. Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin Pharmacother. 2002;3:845\u201356.","journal-title":"Expert Opin Pharmacother"},{"key":"872_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet\u2019s disease. Mediators Inflamm. 2002;11:87\u201393.","journal-title":"Mediators Inflamm"},{"key":"872_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1345\/aph.1D361","volume":"38","author":"M Sayarlioglu","year":"2004","unstructured":"Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behcet\u2019s disease. Ann Pharmacother. 2004;38:901\u20132.","journal-title":"Ann Pharmacother"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"PH Goossens","year":"2001","unstructured":"Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet\u2019s syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60:637.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"872_CR11","doi-asserted-by":"publisher","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61","author":"PP Sfikakis","year":"2002","unstructured":"Sfikakis PP. Behcet\u2019s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61(Suppl 2):ii51\u20133.","journal-title":"Ann Rheum Dis"},{"key":"872_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet. 2001;358:295\u20136.","journal-title":"Lancet"},{"key":"872_CR13","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"872_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21:2.","journal-title":"Arthritis Res Ther"},{"key":"872_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000289205","volume":"11","author":"PP Sfikakis","year":"2010","unstructured":"Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180\u2013210.","journal-title":"Curr Dir Autoimmun"},{"key":"872_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, et al. Behcet\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120\u201330.","journal-title":"Jpn J Ophthalmol"},{"key":"872_CR17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"872_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10384-013-0283-3","volume":"58","author":"T Kawaguchi","year":"2014","unstructured":"Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, et al. Clinical course of patients with Behcet\u2019s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75\u201380.","journal-title":"Jpn J Ophthalmol"},{"key":"872_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","volume":"30","author":"A Adan","year":"2010","unstructured":"Adan A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet\u2019s disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577\u201381.","journal-title":"Int Ophthalmol"},{"key":"872_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468\u201374.","journal-title":"Ocul Immunol Inflamm"},{"key":"872_CR21","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.40235","volume":"69","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, et al. Brief report: drug-free long-term remission in severe Behcet\u2019s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69:2380\u20135.","journal-title":"Arthritis Rheumatol"},{"key":"872_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316892","author":"H Keino","year":"2020","unstructured":"Keino H, Watanabe T, Nakayama M, Komagata Y, Fukuoka K, Okada AA. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2020. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316892.","journal-title":"Br J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-021-00872-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T15:03:55Z","timestamp":1635087835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-021-00872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s10384-021-00872-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"2 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Ida, None; M. Takeuchi, None; M. Ishihara, None; E. Shibuya, None; T. Yamane, None; Y. Hasumi, None; S. Kawano, None; I. Kimura, None; N. Mizuki, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}